Entropy-driven binding of gut bacterial β-glucuronidase inhibitors ameliorates irinotecan-induced toxicity

Hsien-Ya Lin, Chia-Yu Chen, Ting-Chien Lin and colleagues perform structure-guided modifications of the compound uronic isofagomaine in order to engineer a highly specific and potent inhibitor of gut bacterial β-glucuronidases (GUSs). The authors present eight crystal structures and demonstrate in v...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hsien-Ya Lin, Chia-Yu Chen, Ting-Chien Lin, Lun-Fu Yeh, Wei-Che Hsieh, Shijay Gao, Pierre-Alain Burnouf, Bing-Mae Chen, Tung-Ju Hsieh, Punsaldulam Dashnyam, Yen-Hsi Kuo, Zhijay Tu, Steve R. Roffler, Chun-Hung Lin
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/fb39bb5584a546bea3aca76fb3fd4c02
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Hsien-Ya Lin, Chia-Yu Chen, Ting-Chien Lin and colleagues perform structure-guided modifications of the compound uronic isofagomaine in order to engineer a highly specific and potent inhibitor of gut bacterial β-glucuronidases (GUSs). The authors present eight crystal structures and demonstrate in vivo efficacy of the optimised C6-alkyl derivative inhibitor in mice models. This study may enhance the development of inhibitors of microbial GUS for use in colorectal cancer therapy to minimize the undesired side effects of irinotecan treatment.